{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T14:21:06Z","timestamp":1792678866729,"version":"4.5.0"},"reference-count":50,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T00:00:00Z","timestamp":1769472000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thebreastonline.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Breast"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.breast.2026.104715","type":"journal-article","created":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T17:08:55Z","timestamp":1769792935000},"page":"104715","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Predicting progression-free survival in hormone-receptor positive (HR+\/HER2\u2013) metastatic breast cancer (MBC) treated with CDK4\/6 inhibitors: A machine learning approach"],"prefix":"10.1016","volume":"86","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-2023-8223","authenticated-orcid":false,"given":"Sergio","family":"Pannunzio","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1853-4927","authenticated-orcid":false,"given":"Luca","family":"Mastrantoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noemi","family":"Maliziola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-3363-8512","authenticated-orcid":false,"given":"Letizia","family":"Pontolillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanna","family":"Garufi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Di Monte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Emiliani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margherita","family":"Sgambato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Cardillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8371-7087","authenticated-orcid":false,"given":"Antonella","family":"Palazzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Armando","family":"Orlandi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giampaolo","family":"Tortora","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emilio","family":"Bria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.breast.2026.104715_bib1","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"issue":"12","key":"10.1016\/j.breast.2026.104715_bib2","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1016\/j.annonc.2020.09.010","article-title":"5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5)","volume":"31","author":"Cardoso","year":"2020","journal-title":"Ann Oncol"},{"issue":"5","key":"10.1016\/j.breast.2026.104715_bib3","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1200\/OP.21.00384","article-title":"Clinical review on the management of hormone receptor\u2013positive metastatic breast cancer","volume":"18","author":"McAndrew","year":"2022","journal-title":"JCO Oncol Pract"},{"issue":"2","key":"10.1016\/j.breast.2026.104715_bib4","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/S1470-2045(19)30804-6","article-title":"CDK4\/6 inhibitor treatment for patients with hormone receptor-positive, HER2-negative, advanced or metastatic breast cancer: a US Food and Drug Administration pooled analysis","volume":"21","author":"Gao","year":"2020","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.breast.2026.104715_bib5","first-page":"1","article-title":"Determinants of response to CDK4\/6 inhibitors in the real-world setting","volume":"7","author":"Witkiewicz","year":"2023","journal-title":"npj Precis Oncol"},{"issue":"3","key":"10.1016\/j.breast.2026.104715_bib6","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1093\/annonc\/mdx784","article-title":"Polyclonal RB1 mutations and acquired resistance to CDK 4\/6 inhibitors in patients with metastatic breast cancer","volume":"29","author":"Condorelli","year":"2018","journal-title":"Ann Oncol"},{"key":"10.1016\/j.breast.2026.104715_bib7","first-page":"1","article-title":"Pooled ctDNA analysis of MONALEESA phase III advanced breast cancer trials","author":"Andr\u00e9","year":"2023","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.breast.2026.104715_bib8","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1158\/1078-0432.CCR-19-0751","article-title":"Biomarker analyses of response to cyclin-dependent kinase 4\/6 inhibition and endocrine therapy in women with treatment-na\u00efve metastatic breast cancer","volume":"26","author":"Finn","year":"2020","journal-title":"Clin Cancer Res"},{"issue":"14","key":"10.1016\/j.breast.2026.104715_bib9","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1200\/JCO.18.00925","article-title":"Cyclin E1 expression and palbociclib efficacy in previously treated hormone receptor-positive metastatic breast cancer","volume":"37","author":"Turner","year":"2019","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.breast.2026.104715_bib10","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1016\/j.ccell.2017.11.006","article-title":"Genomic aberrations that activate D-type cyclins are associated with enhanced sensitivity to the CDK4 and CDK6 inhibitor abemaciclib","volume":"32","author":"Gong","year":"2017","journal-title":"Cancer Cell"},{"issue":"4","key":"10.1016\/j.breast.2026.104715_bib11","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1016\/j.ccell.2020.03.010","article-title":"Mechanisms of sensitivity and resistance to CDK4\/6 inhibition","volume":"37","author":"\u00c1lvarez-Fern\u00e1ndez","year":"2020","journal-title":"Cancer Cell"},{"issue":"6","key":"10.1016\/j.breast.2026.104715_bib12","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1016\/j.ccell.2018.11.006","article-title":"Loss of the FAT1 tumor suppressor promotes resistance to CDK4\/6 inhibitors via the hippo pathway","volume":"34","author":"Li","year":"2018","journal-title":"Cancer Cell"},{"issue":"1","key":"10.1016\/j.breast.2026.104715_bib13","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41467-019-09068-2","article-title":"Aberrant FGFR signaling mediates resistance to CDK4\/6 inhibitors in ER+ breast cancer","volume":"10","author":"Formisano","year":"2019","journal-title":"Nat Commun"},{"issue":"6","key":"10.1016\/j.breast.2026.104715_bib14","first-page":"1","article-title":"Systematic review of molecular biomarkers predictive of resistance to CDK4\/6 inhibition in metastatic breast cancer","author":"Asghar","year":"2022","journal-title":"JCO Precis Oncol"},{"issue":"5","key":"10.1016\/j.breast.2026.104715_bib15","doi-asserted-by":"crossref","DOI":"10.3390\/diagnostics13050987","article-title":"Mechanisms of resistance to CDK4\/6 inhibitors and predictive biomarkers of response in HR+\/HER2-Metastatic breast cancer\u2014A review of the literature","volume":"13","author":"Stanciu","year":"2023","journal-title":"Diagnostics"},{"issue":"25","key":"10.1016\/j.breast.2026.104715_bib16","doi-asserted-by":"crossref","first-page":"2961","DOI":"10.1200\/JCO.2016.67.3061","article-title":"Plasma ESR1 mutations and the treatment of estrogen receptor-positive advanced breast cancer","volume":"34","author":"Fribbens","year":"2016","journal-title":"J Clin Oncol"},{"issue":"13","key":"10.1016\/j.breast.2026.104715_bib17","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1200\/JCO.20.02977","article-title":"Correlative biomarker analysis of intrinsic subtypes and efficacy across the MONALEESA phase III studies","volume":"39","author":"Prat","year":"2021","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.breast.2026.104715_bib18","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12859-022-04965-8","article-title":"Breast cancer prediction with transcriptome profiling using feature selection and machine learning methods","volume":"23","author":"Taghizadeh","year":"2022","journal-title":"BMC Bioinf"},{"issue":"1","key":"10.1016\/j.breast.2026.104715_bib19","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1038\/s41591-022-02160-z","article-title":"The next generation of evidence-based medicine","volume":"29","author":"Subbiah","year":"2023","journal-title":"Nat Med"},{"issue":"1","key":"10.1016\/j.breast.2026.104715_bib20","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-025-87622-3","article-title":"Leveraging survival analysis and machine learning for accurate prediction of breast cancer recurrence and metastasis","volume":"15","author":"Noman","year":"2025","journal-title":"Sci Rep"},{"key":"10.1016\/j.breast.2026.104715_bib21","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.breast.2019.11.009","article-title":"Machine learning with multiparametric magnetic resonance imaging of the breast for early prediction of response to neoadjuvant chemotherapy","volume":"49","author":"Lo","year":"2020","journal-title":"Breast"},{"issue":"7894","key":"10.1016\/j.breast.2026.104715_bib22","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1038\/s41586-021-04278-5","article-title":"Multi-omic machine learning predictor of breast cancer therapy response","volume":"601","author":"Sammut","year":"2022","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.breast.2026.104715_bib23","doi-asserted-by":"crossref","DOI":"10.1038\/s41523-025-00727-w","article-title":"Accessible model predicts response in hormone receptor positive HER2 negative breast cancer receiving neoadjuvant chemotherapy","volume":"11","author":"Mastrantoni","year":"2025","journal-title":"npj Breast Cancer"},{"issue":"17","key":"10.1016\/j.breast.2026.104715_bib24","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1200\/JCO.21.02439","article-title":"Intelligent vacuum-assisted biopsy to identify breast cancer patients with pathologic complete response (ypT0 and ypN0) after neoadjuvant systemic treatment for omission of breast and axillary surgery","volume":"40","author":"Pfob","year":"2022","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1016\/j.breast.2026.104715_bib25","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1016\/S1470-2045(22)00613-1","article-title":"Eliminating breast surgery for invasive breast cancer in exceptional responders to neoadjuvant systemic therapy: a multicentre, single-arm, phase 2 trial","volume":"23","author":"Kuerer","year":"2022","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.breast.2026.104715_bib26","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2023-078378","article-title":"TRIPOD+AI statement: updated guidance for reporting clinical prediction models that use regression or machine learning methods","author":"Collins","year":"2024","journal-title":"Br Med J"},{"issue":"8","key":"10.1016\/j.breast.2026.104715_bib27","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1093\/annonc\/mdy192","article-title":"4th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 4)","volume":"29","author":"Cardoso","year":"2018","journal-title":"Ann Oncol"},{"key":"10.1016\/j.breast.2026.104715_bib28","first-page":"437","volume":"vol. 14","author":"Wolff","year":"2023"},{"issue":"1","key":"10.1016\/j.breast.2026.104715_bib29","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa2203690","article-title":"Trastuzumab deruxtecan in previously treated HER2-Low advanced breast cancer","volume":"387","author":"Modi","year":"2022","journal-title":"N Engl J Med"},{"issue":"22","key":"10.1016\/j.breast.2026.104715_bib30","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.1093\/jnci\/djr393","article-title":"Assessment of Ki67 in breast cancer: recommendations from the international Ki67 in breast cancer working group","volume":"103","author":"Dowsett","year":"2011","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.breast.2026.104715_bib31","article-title":"Early versus deferred use of CDK4\/6 inhibitors in advanced breast cancer: circulating tumor DNA analysis of a randomized phase 3 trial","volume":"2","author":"Jongbloed","year":"2025","journal-title":"Nat Med"},{"issue":"2","key":"10.1016\/j.breast.2026.104715_bib32","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1056\/NEJMoa2501796","article-title":"Overall survival with inavolisib in PIK3CA -Mutated advanced breast cancer","volume":"393","author":"Jhaveri","year":"2025","journal-title":"N Engl J Med"},{"issue":"12_Supplement","key":"10.1016\/j.breast.2026.104715_bib33","doi-asserted-by":"crossref","DOI":"10.1158\/1557-3265.SABCS24-GS3-09","article-title":"Abstract GS3-09: multimodal integration of real world clinical and genomic data for the prediction of CDK4\/6 inhibitors outcomes in patients with HR+\/HER2- metastatic breast cancer","volume":"31","author":"Moiso","year":"2025","journal-title":"Clin Cancer Res"},{"issue":"16_suppl","key":"10.1016\/j.breast.2026.104715_bib34","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1200\/JCO.2024.42.16_suppl.1074","article-title":"Predicting CDK4\/6 inhibitors outcomes in pts with HR+\/HER2- metastatic breast cancer: a machine learning approach","volume":"42","author":"Moiso","year":"2024","journal-title":"J Clin Oncol"},{"issue":"C","key":"10.1016\/j.breast.2026.104715_bib35","article-title":"Comparison of machine learning and deep learning models for survival prediction in early-stage hormone receptor-positive\/HER2-negative breast cancer receiving neoadjuvant chemotherapy","volume":"10","author":"Mastrantoni","year":"2025","journal-title":"ESMO Real World Data Digit Oncol"},{"issue":"5","key":"10.1016\/j.breast.2026.104715_bib36","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1200\/CCI.21.00025","article-title":"Model development of CDK4\/6 predicted efficacy in patients with hormone receptor\u2013positive, human epidermal growth factor receptor 2\u2013Negative advanced or metastatic breast cancer","author":"Mason","year":"2021","journal-title":"JCO Clin Cancer Informatics"},{"issue":"1","key":"10.1016\/j.breast.2026.104715_bib37","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12885-021-07968-5","article-title":"Risk and prognostic factors of breast cancer with liver metastases","volume":"21","author":"Ji","year":"2021","journal-title":"BMC Cancer"},{"issue":"1","key":"10.1016\/j.breast.2026.104715_bib38","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41523-022-00499-7","article-title":"Histology-based survival outcomes in hormone receptor-positive metastatic breast cancer treated with targeted therapies","volume":"8","author":"Mouabbi","year":"2022","journal-title":"npj Breast Cancer"},{"issue":"20","key":"10.1016\/j.breast.2026.104715_bib39","doi-asserted-by":"crossref","first-page":"5310","DOI":"10.1158\/1078-0432.CCR-20-1764","article-title":"A phase II study of abemaciclib in patients with brain metastases secondary to hormone receptor-positive breast cancer","volume":"26","author":"Tolaney","year":"2020","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.breast.2026.104715_bib40","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.ejca.2020.11.030","article-title":"Machine learning and natural language processing (NLP) approach to predict early progression to first-line treatment in real-world hormone receptor-positive (HR+)\/HER2-negative advanced breast cancer patients","volume":"144","author":"Ribelles","year":"2021","journal-title":"Eur J Cancer"},{"issue":"1","key":"10.1016\/j.breast.2026.104715_bib41","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41523-023-00574-7","article-title":"Radiomic predicts early response to CDK4\/6 inhibitors in hormone receptor positive metastatic breast cancer","volume":"9","author":"Khorrami","year":"2023","journal-title":"npj Breast Cancer"},{"issue":"2","key":"10.1016\/j.breast.2026.104715_bib42","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1093\/oncolo\/oyad293","article-title":"Circulating tumor cells prediction in hormone receptor positive HER2-Negative advanced breast cancer: a retrospective analysis of the MONARCH 2 trial","volume":"29","author":"Gerratana","year":"2024","journal-title":"Oncologist"},{"issue":"December 2018","key":"10.1016\/j.breast.2026.104715_bib43","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.critrevonc.2018.12.004","article-title":"The clinical use of circulating tumor cells (CTCs) enumeration for staging of metastatic breast cancer (MBC): international expert consensus paper","volume":"134","author":"Cristofanilli","year":"2019","journal-title":"Crit Rev Oncol Hematol"},{"issue":"April","key":"10.1016\/j.breast.2026.104715_bib44","article-title":"The impact of liquid biopsy in breast cancer: redefining the landscape of non-invasive precision oncology","volume":"8","author":"Malik","year":"2025","journal-title":"J Liq Biopsy"},{"key":"10.1016\/j.breast.2026.104715_bib45","series-title":"Circulating tumor cells prediction in hormone receptor positive HER2-Negative advanced breast cancer : a retrospective analysis of the MONARCH 2 trial","first-page":"1","author":"Gerratana","year":"2023"},{"key":"10.1016\/j.breast.2026.104715_bib46","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1056\/NEJMoa2502929","article-title":"First-line camizestrant for emerging ESR1 -Mutated advanced breast cancer","author":"Bidard","year":"2025","journal-title":"N Engl J Med"},{"issue":"January","key":"10.1016\/j.breast.2026.104715_bib47","first-page":"1","article-title":"The likelihood of being helped or harmed as a patient-centred tool to assess cyclin dependent kinase 4\/6 inhibitors clinical impact and safety in metastatic breast cancer: a systematic review and sensitivity-analysis","volume":"56","author":"Mastrantoni","year":"2023","journal-title":"eClinicalMedicine"},{"issue":"13","key":"10.1016\/j.breast.2026.104715_bib48","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/cancers14133159","article-title":"Genomic markers of CDK 4\/6 inhibitor resistance in hormone receptor positive metastatic breast cancer","volume":"14","author":"Lee","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"2","key":"10.1016\/j.breast.2026.104715_bib49","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1007\/s40487-021-00162-4","article-title":"A real-world evidence study of CDK4\/6 inhibitor treatment patterns and outcomes in metastatic breast cancer by germline BRCA mutation status","volume":"9","author":"Collins","year":"2021","journal-title":"Oncol Ther"},{"issue":"April","key":"10.1016\/j.breast.2026.104715_bib50","article-title":"Impact of germline BRCA1\/2 status on outcomes for patients with HR+\/HER2- metastatic breast cancer treated with CDK4\/6 inhibitors: a systematic review and meta-analysis","volume":"83","author":"Bottosso","year":"2025","journal-title":"Breast"}],"container-title":["The Breast"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960977626000251?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960977626000251?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T21:31:50Z","timestamp":1775683910000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0960977626000251"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":50,"alternative-id":["S0960977626000251"],"URL":"https:\/\/doi.org\/10.1016\/j.breast.2026.104715","relation":{},"ISSN":["0960-9776"],"issn-type":[{"value":"0960-9776","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Predicting progression-free survival in hormone-receptor positive (HR+\/HER2\u2013) metastatic breast cancer (MBC) treated with CDK4\/6 inhibitors: A machine learning approach","name":"articletitle","label":"Article Title"},{"value":"The Breast","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.breast.2026.104715","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"104715"}}